Neoleukin Therapeutics, Inc. (NLTX)

$0.6346

-0.03 (-4.59%)
Rating:
Recommendation:
-
Symbol NLTX
Price $0.6346
Beta 1.062
Volume Avg. 0.25M
Market Cap 27.021M
Shares () -
52 Week Range 0.62-8.012
1y Target Est -
DCF Unlevered NLTX DCF ->
DCF Levered NLTX LDCF ->
ROE -41.08% Strong Sell
ROA -40.97% Strong Sell
Operating Margin -
Debt / Equity 14.63% Neutral
P/E -
P/B 0.27 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NLTX news


Dr. Jonathan Drachman
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Global Market

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.